EVIDENCE LIBRARY
Hypertensive-Patient Meta-Analysis Found Favorable Remimazolam Estimates but Insufficient Information Size
A six-study meta-analysis favored remimazolam over propofol for selected induction hemodynamic outcomes. Its trial-sequential analysis remained inconclusive, qualifying the conventional significance tests.
A six-study meta-analysis favored remimazolam over propofol for selected induction hemodynamic outcomes. Its trial-sequential analysis remained inconclusive, qualifying the conventional significance tests.
What was pooled
Song and colleagues examined randomized trials of hypertensive adults undergoing anesthesia induction. The pooled risk ratio for hypotension was 0.711, with a 95% confidence interval of 0.545–0.929. Bradycardia also favored remimazolam in the conventional pooled analysis.
Minimum pressure and heart-rate estimates differed between groups, but some outcomes showed substantial heterogeneity. The results concern induction in the included hypertensive populations, not every stage of anesthesia.
Why information size changes the interpretation
Trial-sequential analysis asks whether accumulating evidence is sufficient under a specified monitoring framework. None of the outcomes reached the required information size. A conventional p-value and an inconclusive sequential analysis can therefore coexist.
Small studies, varying protocols, and high heterogeneity for some continuous outcomes constrain the stability of the pooled estimates. The paper calls for larger trials rather than treating its apparent advantage as settled.
Use in testimony
Explain the outcome and uncertainty instead of saying that the newer benzodiazepine is categorically safer. The review cannot establish the cause of an individual pressure drop or guarantee protection in a patient with different comorbidities, co-medications, or anesthetic circumstances.
Source paper
Original analysis of the supplied journal article, identified as PMC13244169.